Last mentioned: Mar 13, 2026
Lorundrostat PDUFA Date
Target date for FDA decision on Mineralys' lead product candidate.
Nektar Phase 3 Launch
Nektar plans first patient randomization for its Atopic Dermatitis program.
Mineralys NDA Acceptance
FDA accepts Mineralys' NDA for lorundrostat for uncontrolled hypertension.
EHang Record Deliveries
EHang closes Q4 with 100 eVTOL units delivered and first GAAP profit.
HeartBeam FDA Clearance
HeartBeam secures 510(k) clearance for 12-lead ECG synthesis software.
The Q4 2025 earnings cycle marks a pivot toward commercial maturity for high-growth ventures, highlighted by Mineralys Therapeutics' FDA filing and EHang's first GAAP-profitable quarter. These results signal a de-risking phase for investors as pre-revenue startups transition into regulated, revenue-generating entities.
EHang (EH) achieved its first quarterly GAAP profit on record eVTOL deliveries, signaling a commercial inflection point for Advanced Air Mobility. Simultaneously, Vuzix (VUZI) reported a 76% revenue surge in smart glasses and waveguide technology, underscoring robust demand for dual-use augmented reality systems.
Mineralys (MLYS) and Vuzix (VUZI) reported Q4 2025 results, highlighting divergent but critical paths in healthcare innovation: the clinical validation of next-generation hypertension therapies and the operational scaling of augmented reality in surgical settings. While Mineralys focuses on pivotal trial readouts for lorundrostat, Vuzix is navigating a transition toward OEM and high-margin medical software solutions.